23:05 , Jan 18, 2018 |  BC Innovations  |  Translation in Brief

A notch for tankyrase

New York University School of Medicine researchers have identified a multitude of tankyrase targets, including factors in the Notch and Wnt/β-catenin pathways, that offer new opportunities for tankyrase inhibitors in cancer. In a Nature Communications study...
21:45 , Jul 13, 2017 |  BC Innovations  |  Targets & Mechanisms

Insider signaling

With evidence mounting that cell surface receptors keep signaling after they are internalized, a Takeda-backed study from Monash University has shown how the phenomenon could solve the riddle of why antagonists of the substance P...
20:18 , Jul 7, 2017 |  BC Week In Review  |  Financial News

CIRM awards $44M in grants

The California Institute for Regenerative Medicine awarded more than $44 million over four grants to develop stem cell therapies to treat stroke, a fetal blood disorder and acute myelogenous leukemia (AML). CIRM awarded $20 million to...
22:22 , Jun 30, 2017 |  BC Extra  |  Financial News

CIRM awards $44M in grants

The California Institute for Regenerative Medicine awarded more than $44 million over four grants to develop stem cell therapies to treat stroke, a fetal blood disorder and acute myelogenous leukemia (AML). CIRM awarded $20 million...
16:58 , May 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Cell culture and mouse studies identified a JAG2-targeting MT-TL1 fragment that could help treat colorectal cancer. The fragment consisted of a dicer 1 ribonuclease type III (DICER1)-cleaved form of MT-TL1 and targeted the...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
20:33 , Apr 21, 2017 |  BC Week In Review  |  Clinical News

Brontictuzumab: Ph Ib discontinued

OncoMed said it will discontinue an open-label, dose-escalation, U.S. Phase Ib trial in mCRC patients after data showed that third-line treatment with IV brontictuzumab plus Lonsurf trifluridine/tipiracil was not well tolerated and led to grade...
19:00 , Apr 17, 2017 |  BC Extra  |  Clinical News

OncoMed reeling after latest Phase II failure

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) sank $0.83 (17%) to $4.01 on Monday after it said tarextumab (OMP-59R5) failed to significantly extend progression-free survival (PFS) in the Phase II PINNACLE trial as a first-line treatment for extensive-stage...
22:57 , Apr 7, 2017 |  BioCentury  |  Emerging Company Profile

Up a notch

By targeting a protein all Notch receptors use to turn on oncogenes, Cellestia Biotech AG’s molecules could treat more patients than therapies against individual Notch receptors or ligands, with less toxicity than other pan-Notch inhibitors. The...
18:00 , Feb 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL) Cell culture and mouse studies suggest inhibition of eIF-2α could help treat T cell ALL. Comparative gene expression analyses of a mouse T cell ALL cell line treated with a Notch...